Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Adipose-derived Stem Cells in COPD
NCT02216630Phase 2Completed
- Sponsor
- Kimera Society
- Start
- Aug 2014
- Primary completion
- Jul 2017
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous adipose-derived mesenchymal stromal cells in chronic obstructive pulmonary disease (COPD), sponsored by Kimera Society. Primary endpoints: Forced Expiratory Volume in 1 Second Decline at 12 months and Number of Adverse Events at 12 months. Started Aug 2014; status: completed.
02
Drugs
autologous adipose-derived mesenchymal stromal cells
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02216630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02216630.